medigraphic.com
Instituto Nacional de Salud Pública

2013, Number 2

Next >>

salud publica mex 2013; 55 (2)

Cartas al editor

Language: Spanish
References: 45
Page: 149-152
PDF size: 250.33 Kb.


Text Extraction

No abstract


REFERENCES

  1. Reyes PA. La vida y obra de Carlos Chagas a cien años de la descripción de la enfermedad de Chagas-Mazza. Arch Cardiol Mex 2009; 79 (4): 237-239.

  2. Cruz-Reyes A, Pickering-López JM. Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years- a review. Mem Inst Oswaldo Cruz, Rio de Janeiro 2006;101: 345-354.

  3. Luquetti AO, Espinoza B, Martínez I, Hernández-Becerril N, Ponce C, Ponce E, et al. Performance levels of four Latin American laboratories for the serodiagnosis of Chagas disease in Mexican sera samples. Mem Inst Oswaldo Cru, Rio de Janeiro 2009;104: 797-800.

  4. Guzman-Bracho MC. Epidemiology of Chagas disease in Mexico: an update 2001. Trends Parasitol 2002;17:372-376.

  5. Mazariego-Arana MA, Monteón-Padilla VM, Ballinas-Verdugo M, Hernández-Becerril N, Alejandre-Aguilar R, Reyes PA. Seroprevalence of human Trypanosoma cruzi infection in different geographical zones of Chiapas, México. Rev Soc Bras Med Trop 2001;34: 453-458.

  6. Capps L, Begoña A. Chagas cardiomyopathy and serological testing in a small rural hospital in Chiapas,Mexico. Pan Amer J Health 2004;15: 337-340.

  7. Bolado-Martinez E, Perez-Mendoza A, Alegria-Morquecho FM, Candia-Plata M del C, Aguayo-Verdugo M del R, Alvarez-Hernandez G. DNA mutations associated to rifampicin or isoniazid resistance in M. tuberculosis clinical isolates from Sonora, Mexico. Salud Publica Mex 2012;54:167-170.

  8. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.

  9. Pozzi G, Meloni M, Iona E, Orru G, Thoresen OF, Ricci ML, et al. rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin Microbiol 1999;37:1197-1199.

  10. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol 2002;40:4435-4438.

  11. Chen L, Gan X, Li N, Wang J, Li K, Zhang H. rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China. J Antimicrob Chemother 2010;65:1299-1301.

  12. Alvarado-Esquivel C, Rossau R, Martinez-Garcia S, Cisneros-Martinez JA, Mijs W, Nevarez-Najera A, et al.Characterization of rpoB gene mutations in rifampicin resistant Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients at 5 Mexican public hospitals. Rev Invest Clin 2001;53:526-530.

  13. Lopez-Alvarez R, Badillo-Lopez C, Cerna-Cortes JF, Castillo-Ramirez I, Rivera-Gutierrez S, Helguera-Repetto AC, et al. First insights into the genetic diversity of Mycobacterium tuberculosis isolates from HIV-infected Mexican patients and mutations causing multidrug resistance. BMC Microbiol 2010;10:82.

  14. Varma-Basil M, El-Hajj H, Colangeli R, Hazbon MH, Kumar S, Bose M, et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates from India and Mexico by a molecular beacon assay. J Clin Microbiol 2004;42:5512-5516.

  15. Viader-Salvado JM, Luna-Aguirre CM, Reyes-Ruiz JM, Valdez-Leal R, del Bosque-Moncayo Mde L, Tijerina-Menchaca R, et al. Frequency of mutations in rpoB and codons 315 and 463 of katG in rifampin- and/or isoniazid-resistant Mycobacterium tuberculosis isolates from northeast Mexico. Microb Drug Resist 2003;9:33-38.

  16. Bobadilla-del-Valle M, Ponce-de-Leon A, Arenas-Huertero C, Vargas-Alarcon G, Kato-Maeda M, Small PM, et al. rpoB Gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism. Emerg Infect Dis 2001;7:1010-1013.

  17. Molina-Torres CA, Moreno-Torres E, Ocampo-Candiani J, Rendon A, Blackwood K, Kremer K, et al. Mycobacterium tuberculosis spoligotypes in Monterrey, Mexico. J Clin Microbiol 2010;48:448-455.

  18. Garza-Gonzalez E, Gonzalez GM, Renteria A, Cruz-Pulido W, Rivera G, Bocanegra-Garcia V. A pyrosequencing method for molecular monitoring of regions in the inhA, ahpC and rpoB genes of Mycobacterium tuberculosis. Clin Microbiol Infect 2010;16:607-612.

  19. Zenteno-Cuevas R, Zenteno JC, Cuellar A, Cuevas B, Sampieri CL, Riviera JE, et al. Mutations in rpoB and katG genes in Mycobacterium isolates from the Southeast of Mexico. Mem Inst Oswaldo Cruz 2009;104:468-472.

  20. Ramaswamy SV, Dou SJ, Rendon A, Yang Z, Cave MD, Graviss EA. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico. J Med Microbiol 2004;53:107-113.

  21. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988;202:45-58.

  22. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-650.

  23. Heep M, Brandstatter B, Rieger U, Lehn N, Richter E, Rusch-Gerdes S, et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001;39:107-110.

  24. Bolado-Martinez E, Perez-Mendoza A, Alegria-Morquecho FM, Candia-Plata M del C, Aguayo-Verdugo M del R, Alvarez-Hernandez G. DNA mutations associated to rifampicin or isoniazid resistance in M. tuberculosis clinical isolates from Sonora, Mexico. Salud Publica Mex 2012;54:167-170.

  25. WHO. Implementing the Stop TB strategy: a handbook for national tuberculosis control programmes. Geneva: World Health Organization, 2008 (WHO/HTM/TB/2008.401).

  26. Luo T, Zhao M, Li X, Xu P, Gui X, Pickerill S, et al. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob Agents Chemother 2010;54:1075-1081.

  27. Kozhamkulov U, Akhmetova A, Rakhimova S, Belova E, Alenova A, Bismilda V, et al. Molecular characterization of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan. Jpn J Infect Dis 2011;64:253-255.

  28. Therese KL, Gayathri R, Balasubramanian S, Natrajan S, Madhavan HN. Phenotypic and genotypic characteristics of drug resistance in Mycobacterium tuberculosis isolates from pediatric population of Chennai, India. Indian J Med Microbiol 2012;30:411-417.

  29. Bang H, Park S, Hwang J, Jin H, Cho E, Kim DY, et al. Improved rapid molecular diagnosis of multidrug-resistant tuberculosis using a new reverse hybridization assay, REBA MTB-MDR. J Med Microbiol 2011;60:1447-1454.

  30. Daum LT, Rodriguez JD, Worthy SA, Ismail NA, Omar SV, Dreyer AW, et al. Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis Strains. J Clin Microbiol 2012;50:3831-3837.

  31. Dantas-Torres F. Rocky Mountain Spotted Fever. Lancet Infect Dis 2007; 7: 724-732.

  32. Chen LF, Sexton DJ. What’s new in Rocky Mountain Spotted Fever? Infect Dis Clin N Am 2008; 22: 415-432.

  33. Razzaq S, Schutze GE. Rocky Mountain Spotted Fever: a physician’s challenge. Pediatr Rev 2005; 26: 125-130.

  34. Treadwell TA, Holman RC, Clarke MJ, Krebs JW, Paddock CD, Childs JE. Rocky Mountain Spotted Fever in the United States, 1993-1996. Am J Trop Med Hyg 2000; 63 (1): 21-26.

  35. Openshaw JJ, Swerdlow DL, Krebs JW, Holman RC, Mandel E, Harvey A, et al. Rocky Mountain Spotted Fever in the United States, 2000–2007: Interpreting contemporary increases in Incidence. Am J Trop Med Hyg 2010; 83(1):174-182.

  36. Secretaría de Salud Pública del Estado de Sonora. Caracterización de la Fiebre Manchada debida a Rickettsia rickettsii, a la semana epidemiológica 36, 2012. Dirección General de Servicios de Salud a la Comunidad/Unidad de Inteligencia Epidemiológica y Emergencias en Salud. México: Secretaría de Salud Pública del Estado de Sonora, 2012.

  37. Walker DH. Editorial: Rickettsia rickettsii as virulent as ever. Am J Trop Med Hyg 2002; 66 (5): 448-449.

  38. Kirkland KB, Wilkinson WE, Sexton TJ. Therapeutic delay and mortality in cases of Rocky Mountain Spotted Fever. Clin Inf Dis 1995; 20 (5): 1118-1121.

  39. Buckingham SC, Marshall GS, Schutze GE, Woods CR, Jackson MA, Patterson LER, et al. Clinical and laboratory features, hospital course, and outcome of Rocky Mountain Spotted Fever in children. J Pediatr 2007; 150: 180-184.

  40. Purvis J, Edwards MS. Doxycycline use for rickettsial disease in pediatric patients. Pediatr Dis Infect J 2000; 19 (9): 871-874.

  41. Masters EJ, Olson GS, Weiner SJ, Paddock CD. Rocky Mountain Spotted Fever. A clinician’s dilemma. Arch Intern Med 2003; 163: 769-774.

  42. O’Reilly M, Paddock C, Elchos B, Goddard J, Childs J, Currie M. Physician knowledge of the diagnosis and management of Rocky Mountain Spotted Fever. Mississippi 2002. Ann NY Acad Sci 2003; 990: 295-301.

  43. Álvarez-Hernández G. La Fiebre Manchada de las Montañas Rocosas, una epidemia olvidada. Salud Publica Mex 2010; 52 (2): 1-3.

  44. Childs JE, Paddock CD. Rocky Mountain Spotted Fever. In: Parola P, Raoult D. (Eds.) Rickettsial Diseases. Informa Health Care. France, 2007: 97-116ISBN: 0849376114.

  45. Paddock CD, Greer PW, Ferebee TL, Singleton J, McKechnie DB, Treadwell TA. Hidden mortality attributable to Rocky Mountain Spotted Fever: immunohistochemical detection of fatal, serologically unconfirmed cases. J Infect Dis 1999; 179: 1469-1478.




2020     |     www.medigraphic.com